Disclaimer: The author/website does not have any ownership or affiliate interests, payment, or material support related to the topics discussed.
Better Therapeutics (ticker: $BTTX), a pioneer in developing prescription digital therapeutics to treat cardiometabolic diseases, has announced a groundbreaking partnership with the American College of Lifestyle Medicine (ACLM). This collaboration aims to expand access to AspyreRx, a novel digital therapeutic approach, across 1,400 Federally Qualified Health Centers (FQHCs).
The partnership between Better Therapeutics and ACLM is set to revolutionize diabetes treatment by making AspyreRx more accessible to patients. AspyreRx is an innovative digital therapeutic approach designed to treat type 2 diabetes. It combines lifestyle medicine and digital technologies to help patients manage their condition effectively.
The good news? This partnership will commit more than $2 million in matching funds to train primary care providers in lifestyle medicine within each FQHC and Community Health Center. This initiative aligns with ACLM’s National Training Initiative, which aims to improve diabetes treatment nationwide.
The partnership will significantly impact FQHCs, which provide crucial healthcare services to underserved communities. By expanding access to AspyreRx, this initiative can potentially enhance diabetes care for millions of patients across the country.
Through this initiative, FQHCs will be better equipped to handle the increasing prevalence of type 2 diabetes in the United States. This move is particularly significant considering that diabetes is one of the leading causes of death in the country.
Moreover, the initiative will also provide opportunities for primary care providers within FQHCs and Community Health Centers to receive training in lifestyle…